AI Article Synopsis

  • The study investigates how the drugs maraviroc (MVC) and rapamycin (RAPA) affect liver health in an experimental model of frailty syndrome using mice, as both drugs target overactive CCR5 expression linked to aging.
  • The research found that both drugs significantly reduced levels of proinflammatory cytokines and certain aging-related markers in the liver tissue, suggesting a potential protective effect against liver aging.
  • The conclusion indicates that while MVC and RAPA may help mitigate aging factors in the liver, further research is needed to explore their clinical benefits in humans.

Article Abstract

Cellular senescence and low-grade inflammation favor the acceleration of aging. The liver is an essential metabolic organ because changes related to its function are related to age-related diseases. The objective of this study was to evaluate the effects of maraviroc (MVC) and/or rapamycin (RAPA) on liver tissue in an experimental model of frailty syndrome in mice, since MVC and RAPA are two molecules able to decrease CCR5 expression, which is overexpressed in patients with frailty. Methods: Eighty male homozygous IL10KO mice were randomly assigned to one of 4 groups (n = 20): i) IL10KO group; ii) MVC group, iii) RAPA group, and iv) MVC-RAPA group. Liver samples were analyzed. Gene expression quantification and western blotting were also performed. The proinflammatory cytokines IL-6 and IL-18 were decreased in MVC and MVC/RAPA groups, IL-12 was decreased in RAPA and MVC/RAPA groups and TNF-α was decreased in all therapeutic groups. P21 was decreased in RAPA and MVC/RAPA groups, Galactosidase beta-1, was also significantly reduced in all therapeutic groups, as were NF-kB1, NF-kB2 and STAT3. In all groups, mTOR and CCL5 were significantly reduced. CCR5 expression was decreased in the MVC and MVC/RAPA groups. Conclusion: MVC and RAPA may protect against some factors involved in liver aging. More studies will be necessary to verify their clinical applications.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10781157PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0286201PLOS

Publication Analysis

Top Keywords

mvc/rapa groups
16
and/or rapamycin
8
frailty syndrome
8
mvc rapa
8
ccr5 expression
8
groups
8
decreased mvc
8
mvc mvc/rapa
8
decreased rapa
8
rapa mvc/rapa
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!